Business Context and Reporting Period
This Form 8-K is filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on February 16, 2017. The report discloses preliminary unaudited sales estimates for the company's ophthalmology business for the fourth quarter ended December 31, 2016, and includes a management presentation used at investor conferences.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing preliminary sales estimates, but the specific figures are not included in the body of this document.
Material Changes
The filing does not detail specific material changes versus prior periods within the text provided. It serves primarily to announce the issuance of preliminary sales data and a management presentation.
Guidance, Outlook, and Risks
- Disclosure Status: The information furnished under Item 2.02 and Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to its liabilities.
- Forward-Looking Obligations: The Company explicitly states it does not assume any obligation to update the information or exhibits in the future.
- Regulation FD: The filing includes a Regulation FD disclosure regarding a management presentation (Exhibit 99.2).
Investor Verification Checklist
- Verify the specific preliminary sales figures for the fourth quarter of 2016 by reviewing Exhibit 99.1 (Press Release), as they are not listed in the main text.
- Review Exhibit 99.2 for the full management presentation details regarding the company's outlook.
- Confirm the distinction between the registrant name in the filing (Imprimis Pharmaceuticals, Inc.) and any external metadata references.
- Note that the company has disclaimed any obligation to update the preliminary estimates provided in this filing.